Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safer CARS.

Literature DB >> 20357776

Safer CARS.

Helen E Heslop.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2010 PMID： 20357776 PMCID： PMC2862533 DOI： 10.1038/mt.2010.42

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

17 in total

1. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Authors: Laurence J N Cooper; Zaid Al-Kadhimi; Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Adrian Castro; Wen-Chung Chang; Sergio Gonzalez; David Smith; Stephen J Forman; Michael C Jensen
Journal: Blood Date: 2004-10-26 Impact factor: 22.113

2. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors: Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544

3. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors: Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal: N Engl J Med Date: 2006-08-14 Impact factor: 91.245

4. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors: John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal: Nat Biotechnol Date: 2002-01 Impact factor: 54.908

5. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors: Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal: Mol Ther Date: 2010-04 Impact factor: 11.454

6. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Authors: Michael H Kershaw; Jennifer A Westwood; Linda L Parker; Gang Wang; Zelig Eshhar; Sharon A Mavroukakis; Donald E White; John R Wunderlich; Silvana Canevari; Linda Rogers-Freezer; Clara C Chen; James C Yang; Steven A Rosenberg; Patrick Hwu
Journal: Clin Cancer Res Date: 2006-10-15 Impact factor: 12.531

7. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.

Authors: Edus H Warren; Nobuharu Fujii; Yoshiki Akatsuka; Colette N Chaney; Jeffrey K Mito; Keith R Loeb; Ted A Gooley; Michele L Brown; Kevin K W Koo; Kellie V Rosinski; Seishi Ogawa; Aiko Matsubara; Frederick R Appelbaum; Stanley R Riddell
Journal: Blood Date: 2010-01-13 Impact factor: 22.113

8. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Authors: Brian G Till; Michael C Jensen; Jinjuan Wang; Eric Y Chen; Brent L Wood; Harvey A Greisman; Xiaojun Qian; Scott E James; Andrew Raubitschek; Stephen J Forman; Ajay K Gopal; John M Pagel; Catherine G Lindgren; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal: Blood Date: 2008-05-28 Impact factor: 22.113

9. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Authors: Siok-Keen Tey; Gianpietro Dotti; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal: Biol Blood Marrow Transplant Date: 2007-05-29 Impact factor: 5.742

Review 10. Targeting tumours with genetically enhanced T lymphocytes.

Authors: Michel Sadelain; Isabelle Rivière; Renier Brentjens
Journal: Nat Rev Cancer Date: 2003-01 Impact factor: 60.716

40 in total

1. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors: Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal: Cancer Res Date: 2010-10-05 Impact factor: 12.701

Review 2. Genetic modification of T cells.

Authors: Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal: Biol Blood Marrow Transplant Date: 2011-01 Impact factor: 5.742

3. Is it safer CARs that we need, or safer rules of the road?

Authors: Richard P Junghans
Journal: Mol Ther Date: 2010-10 Impact factor: 11.454

4. Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors: David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal: Hum Gene Ther Date: 2011-09-23 Impact factor: 5.695

5. Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors: Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal: Cell Mol Life Sci Date: 2014-04 Impact factor: 9.261

6. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors: Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal: Cancer Immunol Res Date: 2013-07 Impact factor: 11.151